Cardinal Health Inc. (CAH) Q4 2026 (USD): Adj. EPS 2.91 (exp. 2.42), Revenue 63.7bln (exp. 65.15bln), Current FY EPS 12.40-12.60 (exp. 10.78), boosts share buyback by USD 5bln

Mixed prints of this kind from the big drug distributors tend to resolve in favour of the earnings line: the revenue miss is largely a pass-through phenomenon, since distributor top lines are inflated by drug pricing and branded-to-generic mix shifts, and the market has historically treated them as a weak signal relative to per-share earnings and fee income. The split that matters here is between gross margin dollars and reported sales; a large revenue shortfall alongside a clear EPS beat usually means mix, GLP-1 and specialty volume, or contract timing rather than demand. Guidance set materially above consensus has in past episodes for this peer set proven conservative, as management teams in the group have a track record of under-promising and revising upward through the year, so the gap to the prior street number tends to close quickly as analysts re-mark. A buyback top-up of that size alongside a guidance raise is the classic capital-return signal in a sector with steady cash generation, and comparable announcements have historically supported the shares even when the headline revenue line disappoints. The follow-ons worth noting are the call commentary on drug-pricing dynamics and fee-for-service mix, whether the other two large distributors trade in sympathy, and any management colour on what drove the revenue shortfall, since that determines whether the miss is cosmetic or structural. The initial read is that this is an EPS-quality print dressed as a mixed one.